According to FutureWise analysis, the Fecal Occult Testing market in 2025 is US$1.92 billion, and is expected to reach US$2.73 billion by 2033 at a CAGR of 4.5%. The Fecal Occult Testing market is experiencing growth due to the rising incidence of colorectal cancer and a greater focus on early disease detection. Additionally, advancements in diagnostic technologies and increased awareness programs are likely further to promote the expansion of the Fecal Occult Testing market. The colorectal cancer diagnostic market is experiencing significant growth due to several key factors. One major factor is the rising incidence of colorectal cancer, which has led to a greater emphasis on early detection and preventive diagnostics. Additionally, advancements in non-invasive testing technologies and increased awareness among patients about the importance of screening are also contributing to the market's expansion. This growth is particularly driven by the prevalence of colorectal cancer, heightened awareness of non-invasive screening options, and innovations in immunochemical testing technologies.
Improved Testing Technologies
There is an increasing preference for immunochemical fecal occult blood tests (FIT/iFOBT) over traditional guaiac-based tests, due to their greater specificity and lower rate of false positives. The introduction of advanced test kits will improve sensitivity and reliability for early disease detection.
A fecal occult blood test checks for the presence of blood in your stool. To perform this test, a small stool sample is collected and sent to a doctor or laboratory for analysis, typically using a special collection tube or card. The presence of blood in the stool may indicate conditions such as colorectal cancer, polyps, ulcers, or hemorrhoids. There are two types of fecal occult blood tests: the guaiac fecal occult blood test and the immunochemical fecal occult blood test. The guaiac test uses a chemical called guaiac to detect blood, while the immunochemical test employs antibodies to identify blood in the stool. This test is also known as FOBT.
Fecal occult testing (FOBT) is increasingly being promoted due to a rising awareness of the importance of early screening. This type of testing enables quick medical decisions, provides efficient healthcare, enhances quality of life, and reduces mortality rates. A key factor driving the expansion of this market is the growing emphasis on integrated health services, which aim to enhance patient experiences and improve health outcomes. This trend is accompanied by a rising preference for point-of-care diagnostics (POCD). Additionally, the market is experiencing rapid growth due to an aging population, as the likelihood of developing diseases increases with age. In response, various countries are implementing multiple FOBT screening programs for senior citizens. The market is also benefiting from the increased use of minimally invasive (MI) procedures. Moreover, immunochemical fecal occult blood tests (iFOBTs or FITs) are gaining attention because they are easy to use and offer greater clinical sensitivity for detecting malignancies and advanced adenomas. During the forecast period, the increasing availability of FOBT devices through online retail stores is expected to boost market growth further.
FutureWise Market Research has released a report that provides an in-depth analysis of Fecal Occult Testing Market trends that will impact the overall market growth.
Request a Free Sample @
https://www.futurewiseresearch.com/contact.aspx?rpt=11640&type=requestsample
By Product
By End User
By Region
Here’s a regional view of where the most progress is happening:
North America
Competitive Landscape in Fecal Occult Testing Market:
Recent developments by key players in the Fecal Occult Testing Market:
EIKEN CHEMICAL CO., LTD.
Polymedco CDP, LLC
Abbott Laboratories
Quidel Corporation
Buy now the latest version of this report: https://www.futurewiseresearch.com/checkout.aspx?ReportId=11640&license=multi
**Objectives of this Study: **
Flexible Delivery Model: